The first accurate way to diagnose CTE while patients are still alive
For generations, chronic traumatic encephalopathy has delivered its verdict only after death — a diagnosis that arrived too late to matter to the person who carried the disease. Now researchers in Toronto have developed a radiotracer that can detect the tau pathology of CTE in living brains, offering athletes, veterans, and survivors of violence something the field has never been able to provide: a diagnosis while there is still time to act on it. The work does not yet offer a cure, but it opens the door to the clinical trials and treatment development that a diagnosable disease makes possible.
- CTE has long condemned patients to diagnostic limbo — symptoms without confirmation, fear without answers, and no treatment pathway to pursue.
- The new tracer, 18F-OXD-2314, lit up distinctive tau patterns in suspected CTE patients that existing Alzheimer-designed tracers were never built to see.
- Early results are striking: elevated uptake at the gray-white matter junction in affected patients, with zero comparable signal in healthy controls.
- Validation against actual post-mortem CTE brain tissue confirmed the tracer binds to tau pathology in every tested case, lending weight to the living-patient findings.
- Clinical availability could arrive within two years — a compressed timeline that researchers say could finally make treatment trials possible for a disease that currently has none.
For decades, the only certain answer to whether someone had chronic traumatic encephalopathy came from a pathologist examining brain tissue after death. The family would finally know — too late to help. That grim calculus may now be changing.
Researchers at the Centre for Addiction and Mental Health in Toronto have developed a PET imaging technique using a radiotracer called 18F-OXD-2314 that can detect the tau plaques characteristic of CTE in living patients. CTE is a degenerative disease triggered by repeated head impacts, affecting contact sports athletes, military veterans, and survivors of intimate partner violence. Its symptoms — memory loss, mood instability, impulsivity, and eventual dementia — arrive without any confirmed diagnosis or treatment options to meet them.
In a study presented at the 2026 Society of Nuclear Medicine and Molecular Imaging annual meeting, the tracer was administered to three retired athletes with suspected CTE and seven healthy volunteers. The imaging results were clear: in suspected CTE patients, the tracer concentrated at the junction between gray and white matter in patterns entirely absent from healthy controls. When tested against brain tissue from deceased CTE patients, it bound to tau pathology in every case.
The distinction from existing tracers matters. Prior tau PET agents were designed for Alzheimer's disease, where tau accumulates differently than in traumatic encephalopathy — making them poorly suited to detect CTE's specific signature. The new tracer appears calibrated precisely for what CTE looks like in living tissue.
Senior scientist Isabelle Boileau suggested clinical availability could arrive within two years if further studies confirm the findings. For patients currently suspended in diagnostic uncertainty — symptoms present, confirmation impossible, treatment trials inaccessible — an in-life diagnosis would fundamentally change what is possible. It would also signal a broader shift toward precision neuroimaging: tracers designed not for the most prevalent disease, but for the exact pathology being sought.
For decades, the only way to know for certain that someone had chronic traumatic encephalopathy was to wait until they died. A pathologist would examine their brain tissue, look for the telltale tau plaques that mark the disease, and then the family would have their answer—too late to help. Now researchers at the Centre for Addiction and Mental Health in Toronto have developed a PET imaging technique that can detect those same tau plaques while a person is still alive, potentially transforming how we diagnose and treat one of neurology's most stubborn problems.
CTE is a degenerative brain disease triggered by repeated head impacts. It haunts contact sports athletes who spent years absorbing blows on the field, military veterans exposed to blast injuries, and people who have survived intimate partner violence or other traumatic brain injuries. The disease announces itself through a grim catalog of symptoms: memory loss, mood swings, impulsivity, and eventually dementia. There is no cure. There are no approved treatments. Until now, there has been no way to confirm the diagnosis except through autopsy.
The breakthrough centers on a radiotracer called 18F-OXD-2314. In a study presented at the Society of Nuclear Medicine and Molecular Imaging's 2026 annual meeting, researchers gave this tracer to three retired athletes with suspected CTE and seven healthy volunteers, then used PET imaging to track where the tracer accumulated in their brains. The results were striking. In people with suspected CTE, the tracer lit up in distinctive patterns—concentrated at the junction between gray and white matter, and throughout the white matter itself. The healthy controls showed no such uptake. When the researchers tested the tracer against actual brain tissue from deceased CTE patients, it bound to the tau pathology in every case.
What makes this advance significant is that existing tau PET tracers were designed for Alzheimer's disease, where tau pathology follows a different pattern than it does in CTE. Those older tracers miss the specific signature of traumatic encephalopathy. The new tracer, by contrast, appears calibrated to recognize exactly what CTE looks like in living brain tissue. Isabelle Boileau, the senior scientist leading the work, described the potential plainly: if validated, this could provide the first accurate way to diagnose CTE while patients are still alive, opening the door to clinical trials for treatments that have never been possible before.
The timeline is compressed. Boileau suggested that PET imaging for CTE could be available to patients within two years, assuming further studies confirm the early findings. That speed matters. Right now, anyone suspected of having CTE faces a kind of diagnostic limbo—symptoms that match the disease, but no definitive confirmation, and no treatment options to pursue even if confirmation were possible. An in-life diagnosis would change that calculus entirely. It would let clinicians identify patients early, enroll them in treatment trials, and begin to build the evidence base for interventions that simply do not exist today.
The implications extend beyond CTE itself. This work could establish PET imaging as a standard tool for evaluating traumatic brain injury more broadly, and for other neurodegenerative diseases where tau accumulates in patterns different from Alzheimer's. It signals a shift toward precision neuroimaging—using tracers designed not for the most common disease, but for the specific pathology you are trying to find. For athletes, veterans, and survivors of violence who have lived with the fear and uncertainty of undiagnosed neurodegeneration, that shift could mean the difference between hope and resignation.
Notable Quotes
If validated, 18F-OXD-2314 could help provide the first accurate in-life diagnostic biomarker for CTE, and could establish a clinical role for PET in traumatic brain injury and sports- and military-related neurodegeneration.— Isabelle Boileau, senior scientist at Centre for Addiction and Mental Health
The PET imaging for CTE could be available to patients as early as in the next two years, pending further studies.— Isabelle Boileau
The Hearth Conversation Another angle on the story
Why has it taken so long to develop a test for CTE while someone is still alive?
Because CTE's tau pathology looks different from Alzheimer's tau. The tracers we had were built for Alzheimer's, so they were looking for the wrong pattern. It's like having a key that opens most locks but not the one you need.
So this new tracer is specifically tuned to CTE's pattern?
Exactly. They tested it against actual CTE brain tissue from deceased patients and it bound to the pathology in every case. That's the proof that it recognizes what it's supposed to find.
What changes if doctors can diagnose CTE in living patients?
Everything, potentially. Right now there's no treatment because there's been no way to test treatments. You can't run a clinical trial on a disease you can't diagnose. An in-life test opens that door.
Who benefits most immediately?
Athletes and veterans with suspected CTE who are experiencing cognitive decline or mood problems. They could finally get a definitive answer instead of living in uncertainty. And they could potentially enroll in treatment trials.
How soon could this actually be available?
The researchers say within two years, pending validation studies. That's remarkably fast for medical imaging, which usually takes much longer to move from research to clinical use.
What's the catch?
It's still early. They tested it on only three patients with suspected CTE. The sample is small. The real work is scaling up, confirming the findings hold in larger groups, and making sure the test is reliable enough for clinical practice.